Athira Pharma Secures $236M for Breakthrough Breast Cancer Treatment
Athira Pharma acquires lasofoxifene drug rights and raises $236M to advance Phase 3 trials for ESR1-mutant metastatic breast cancer treatment through 2027.
/ 1 item
#ATHA↓